Literature DB >> 12142635

Interference of hematocrit in the tacrolimus II microparticle enzyme immunoassay.

Takafumi Kuzuya1, Yozo Ogura, Yoko Motegi, Natsuko Moriyama, Toshitaka Nabeshima.   

Abstract

The authors studied the effect of hematocrit, bilirubin, and alkaline phosphatase on microparticle enzyme immunoassay for tacrolimus II (MEIA II) using specimens of whole blood obtained from 33 patients undergoing cyclosporine treatment. Tacrolimus was added to these samples at a final concentration of 7.5 microg/L and 15 microg/L. Both coefficients of variation were over 20% (21% at 7.5 macrog/L of tacrolimus and 22% at 15 microg/L of tacrolimus). No correlation was found between bilirubin and tacrolimus concentrations or between alkaline phosphatase and tacrolimus concentrations. On the other hand, negative correlations were found between hematocrit values and tacrolimus concentrations (r2 = 0.47; P < 0.0001 at 7.5 microg/L tacrolimus, r2 = 0.54; P < 0.0001 at 15 microg/L tacrolimus). Negative correlations were also found between hematocrit and the tacrolimus concentration using normal human red blood cells diluted with physiological saline solution (r2 = 0.93; P < 0.0001 at 7.5 microg/L tacrolimus, r2 = 0.91; P < 0.0001 at 15 microg/L tacrolimus). The results showed that the hematocrit interferes with the MEIA II for tacrolimus, and the magnitude of the interference is clinically significant. Beyond the normal range of hematocrit values, caution should be exercised in interpreting results as one may need to compensate for the levels of tacrolimus.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12142635     DOI: 10.1097/00007691-200208000-00008

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  3 in total

Review 1.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

2.  Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.

Authors:  Dirk R J Kuypers; Kathleen Claes; Pieter Evenepoel; Bart Maes; Willy Coosemans; Jacques Pirenne; Yves Vanrenterghem
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  Analytical performance evaluation of the Elecsys® Cyclosporine and Elecsys® Tacrolimus assays on the cobas e411 analyzer.

Authors:  Maki Sasano; Shigeki Kimura; Ikuhiro Maeda; Yoh Hidaka
Journal:  Pract Lab Med       Date:  2017-03-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.